JP2008514721A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008514721A5 JP2008514721A5 JP2007534765A JP2007534765A JP2008514721A5 JP 2008514721 A5 JP2008514721 A5 JP 2008514721A5 JP 2007534765 A JP2007534765 A JP 2007534765A JP 2007534765 A JP2007534765 A JP 2007534765A JP 2008514721 A5 JP2008514721 A5 JP 2008514721A5
- Authority
- JP
- Japan
- Prior art keywords
- mtor inhibitor
- inhibitor according
- administered
- therapy
- aml
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61548504P | 2004-09-30 | 2004-09-30 | |
| PCT/US2005/035047 WO2006039414A2 (en) | 2004-09-30 | 2005-09-30 | Treatment method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008514721A JP2008514721A (ja) | 2008-05-08 |
| JP2008514721A5 true JP2008514721A5 (https=) | 2008-11-13 |
Family
ID=36143059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007534765A Pending JP2008514721A (ja) | 2004-09-30 | 2005-09-30 | 治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080081053A1 (https=) |
| EP (1) | EP1809276A4 (https=) |
| JP (1) | JP2008514721A (https=) |
| AU (1) | AU2005292033A1 (https=) |
| CA (1) | CA2581372A1 (https=) |
| MX (1) | MX2007003790A (https=) |
| WO (1) | WO2006039414A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4547911B2 (ja) | 2002-02-01 | 2010-09-22 | アリアド・ファーマシューティカルズ・インコーポレイテッド | リン含有化合物およびその用途 |
| CA2629714A1 (en) * | 2005-11-14 | 2007-05-24 | Ariad Gene Therapeutics, Inc. | Administration of an mtor inhibitor to treat patients with cancer |
| CA2645633A1 (en) * | 2006-04-05 | 2007-11-01 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| WO2007143212A1 (en) * | 2006-06-02 | 2007-12-13 | Ariad Gene Therapeutics, Inc. | Capecitabine combination therapy |
| US20100266590A1 (en) * | 2006-08-02 | 2010-10-21 | Demetri George D | Combination therapy |
| CN103330694A (zh) * | 2006-11-14 | 2013-10-02 | 阿里亚德医药股份有限公司 | 口服制剂 |
| TWI597061B (zh) * | 2013-02-20 | 2017-09-01 | 國鼎生物科技股份有限公司 | 治療白血病之方法及組成物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5118677A (en) * | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
| US7041654B2 (en) * | 1997-10-03 | 2006-05-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for inducing tumor-specific cytotoxicity |
| JP4547911B2 (ja) * | 2002-02-01 | 2010-09-22 | アリアド・ファーマシューティカルズ・インコーポレイテッド | リン含有化合物およびその用途 |
| AU2003247483A1 (en) * | 2002-05-30 | 2003-12-31 | The Children's Hospital Of Philadelphia | Methods for treatment of acute lymphocytic leukemia |
| AU2003248813A1 (en) * | 2002-07-05 | 2004-01-23 | Beth Israel Deaconess Medical Center | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
-
2005
- 2005-09-30 EP EP05799834A patent/EP1809276A4/en not_active Withdrawn
- 2005-09-30 WO PCT/US2005/035047 patent/WO2006039414A2/en not_active Ceased
- 2005-09-30 US US11/663,940 patent/US20080081053A1/en not_active Abandoned
- 2005-09-30 MX MX2007003790A patent/MX2007003790A/es unknown
- 2005-09-30 JP JP2007534765A patent/JP2008514721A/ja active Pending
- 2005-09-30 AU AU2005292033A patent/AU2005292033A1/en not_active Abandoned
- 2005-09-30 CA CA000000004A patent/CA2581372A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009539769A5 (https=) | ||
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| JP2012526850A5 (https=) | ||
| Zorzi et al. | A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium | |
| JP2012506898A5 (https=) | ||
| RU2013102398A (ru) | Лечение рака крови | |
| WO2009008992A3 (en) | Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2 | |
| JP2009515901A5 (https=) | ||
| RU2009127351A (ru) | Комбинации антифолатного агента в лечении рака | |
| JP2021080296A5 (https=) | ||
| Peterson et al. | Intensive five‐drug combination chemotherapy for adult acute non‐lymphocytic leukemia | |
| JP2020523359A5 (https=) | ||
| JP2008514721A5 (https=) | ||
| JP2017507151A5 (https=) | ||
| JP2010525042A5 (https=) | ||
| WO2017184086A1 (en) | Method of treating liver cancer | |
| Westermann et al. | A systemic hyperthermia oncologic working group trial: ifosfamide, carboplatin, and etoposide combined with 41.8 C whole-body hyperthermia for metastatic soft tissue sarcoma | |
| Kobayashi et al. | Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan | |
| CN102834094B (zh) | 有机化合物的组合产品及其制药用途 | |
| Wang et al. | Preclinical investigation of orally bioavailable, potent KRAS Multi inhibitor JAB-23425 | |
| JP2014500259A (ja) | 血液癌を処置する方法 | |
| CN1917885A (zh) | 抗癌疗法 | |
| JP2021514956A5 (https=) | ||
| RU2678103C2 (ru) | Противоопухолевое средство, содержащее противоопухолевый комплекс платины, и усилитель противоопухолевого эффекта | |
| CN1302777C (zh) | 包括取代的丙烯酰偏端霉素衍生物和放射治疗的抗肿瘤联合疗法 |